Recipharm Advanced Bio began process performance qualification runs for Infant Bacterial Therapeutics’ lead live biotherapeutic product, IBP‑9414, at its Cuxhaven microbial manufacturing facility—advancing the candidate toward commercial supply and process validation for a first‑in‑class LBP. In a related industry finance move, private equity firm Eurazeo invested to back French CRO Excelya’s European expansion and roll‑up strategy. Excelya plans to deploy capital toward acquisitions and AI/automation to optimize trial operations. Both developments highlight upstream investment in manufacturing and trial infrastructure to de‑risk commercialization of complex biological therapies and support faster market entry.